Literature DB >> 15561880

Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.

Donna M MacCallum1, Frank C Odds.   

Abstract

Groups of mice infected intravenously with Candida albicans were treated intraperitoneally with amphotericin B, caspofungin, or fluconazole, starting at intervals before and after challenge. Survival was longest and tissue burdens were most reduced with early treatment, and survival times fell proportionately as treatment was delayed, reinforcing clinical recommendations for the earliest possible initiation of antifungal therapy.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15561880      PMCID： PMC529222          DOI： 10.1128/AAC.48.12.4911-4914.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Current serological and molecular methods in the diagnosis of systemic infections with Candida sp. and Aspergillus sp. in immunocompromised patients with hematological malignancies.

Authors:  D Buchheidt; H Skladny; C Baust; R Hehlmann
Journal:  Antibiot Chemother (1971)       Date:  2000

Review 2.  Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.

Authors:  J L Vincent; E Anaissie; H Bruining; W Demajo; M el-Ebiary; J Haber; Y Hiramatsu; G Nitenberg; P O Nyström; D Pittet; T Rogers; P Sandven; G Sganga; M D Schaller; J Solomkin
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

3.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Authors:  J H Rex; T J Walsh; J D Sobel; S G Filler; P G Pappas; W E Dismukes; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

4.  Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.

Authors:  F Ikeda; Y Wakai; S Matsumoto; K Maki; E Watabe; S Tawara; T Goto; Y Watanabe; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.

Authors:  A Louie; P Banerjee; G L Drusano; M Shayegani; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.

Authors:  B A Arthington-Skaggs; D W Warnock; C J Morrison
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model.

Authors:  L Zarif; J R Graybill; D Perlin; L Najvar; R Bocanegra; R J Mannino
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

9.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.

Authors:  E W van Etten; C van den Heuvel-de Groot; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790
View more
  10 in total

1.  Organ-specific innate immune responses in a mouse model of invasive candidiasis.

Authors:  Michail S Lionakis; Jean K Lim; Chyi-Chia Richard Lee; Philip M Murphy
Journal:  J Innate Immun       Date:  2010-11-09       Impact factor: 7.349

2.  Dose escalation studies with caspofungin against Candida glabrata.

Authors:  Marianna Domán; Renátó Kovács; David S Perlin; Gábor Kardos; Rudolf Gesztelyi; Béla Juhász; Aliz Bozó; László Majoros
Journal:  J Med Microbiol       Date:  2015-06-30       Impact factor: 2.472

Review 3.  Caspofungin: a review of its use in the treatment of fungal infections.

Authors:  Paul L McCormack; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Inhibition of filamentation can be used to treat disseminated candidiasis.

Authors:  Stephen P Saville; Anna L Lazzell; Alexander P Bryant; Angelika Fretzen; Alex Monreal; Erik O Solberg; Carlos Monteagudo; Jose L Lopez-Ribot; G Todd Milne
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

Authors:  William W Hope; George L Drusano; Caroline B Moore; Andrew Sharp; Arnold Louie; Thomas J Walsh; David W Denning; Peter A Warn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

6.  The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

Authors:  William W Hope; Vidmantas Petraitis; Ruta Petraitiene; Tamarra Aghamolla; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

7.  In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis.

Authors:  Patricia M Tavares; Karin Thevissen; Bruno P A Cammue; Isabelle E J A François; Eliana Barreto-Bergter; Carlos P Taborda; Alexandre F Marques; Marcio L Rodrigues; Leonardo Nimrichter
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

8.  Caspofungin disk diffusion breakpoints and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

9.  The Lymphocytic Scavenger Receptor CD5 Shows Therapeutic Potential in Mouse Models of Fungal Infection.

Authors:  María Velasco-de Andrés; Cristina Català; Sergi Casadó-Llombart; Mario Martínez-Florensa; Inês Simões; Joaquín García-Luna; Gustavo Mourglia-Ettlin; Óscar Zaragoza; Esther Carreras; Francisco Lozano
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

10.  Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials.

Authors:  Lutz E Lehmann; Bernd Herpichboehm; Gerald J Kost; Marin H Kollef; Frank Stüber
Journal:  Crit Care       Date:  2010-10-15       Impact factor: 9.097
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.